title: Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez-Trabado
authors.forename: L M
authors.initials: LM
authors.lastname: Fernández Pereira
authors.forename: S
authors.initials: S
authors.lastname: Romero-Chala
authors.forename: J A
authors.initials: JA
authors.lastname: García-Trujillo
authors.forename: C
authors.initials: C
authors.lastname: Cámara Hijón
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000627:therapeutic use; D015551:Autoimmunity; D015549:Basophil Degranulation Test / Q000379:methods*; D001491:Basophils / Q000187:drug effects / Q000276:immunology; D015550:Cell Degranulation / Q000187:drug effects; D002908:Chronic Disease; D016903:Drug Monitoring / Q000379:methods; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D000069444:Omalizumab; D060149:Tetraspanin 30 / Q000378:metabolism; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D060149:Tetraspanin 30; D000069444:Omalizumab